Project Grant HT94252410905

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $391,826 to the University of Pennsylvania on July 16, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate an innovative nanoparticle-based therapeutic platform for breast cancer treatment. The project, which extends through June 30, 2027, focuses on designing biodegradable polyphosphazene nanoparticles (PPNPs) that combine heat shock protein (HSP) inhibitor drug...

This $256,000 National Science Foundation project grant supports the development of novel antibody-brush polymer conjugates with high drug-to-antibody ratios by Window Therapeutics, Inc. The goal is to create the next generation of antibody-drug conjugates for cancer immunotherapy through research and development of antibody-brush polymer conjugates that can load up to 100 drugs per antibody. These conjugates aim to enable immunotherapies to treat immunoresistant cancers like colorectal cancer...

Summary: Liquid Immunotherapeutic Fiducial Eluter (LIFE) Gel for Cervical Cancer The National Cancer Institute awarded Nanocan Therapeutics Corporation a $2.99 million Phase II Small Business Technology Transfer (STTR) Project Grant on September 24, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct the first clinical trial for a novel therapeutic technology targeting advanced cervical cancer. In collaboration with Johns Hopkins University, Nanocan will develop and...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

Federal Grant Award Summary Glow Therapeutics Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I Project Grant from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to develop a light-activatable nanoplatform for targeted delivery of photodynamic therapy (PDT) and chemotherapy to peritoneal metastasis. The award, issued June 15, 2025, with completion targeted for May 31, 2026, supports translation of a...

This $882,000 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the CFDA 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health program, supports research to engineer natural killer (NK) cell-derived extracellular vesicles (EVs) as a nanodrug for tumor-targeted bioimaging and therapy. The awardee, the University of Texas at Tyler, aims to leverage the cancer-targeting capabilities of NK cells to develop...

This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Absco Therapeutics, Inc. (DBA Abscotx) to develop an image-guided intratumoral therapy for treating immunotherapy-resistant solid tumors. The project aims to create an innovative drug delivery platform that can improve the efficacy and safety of biologic cancer therapies, addressing challenges such as poor on-target...

This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...